MoFo Advises Eton Pharmaceuticals on Asset Sale to Dr. Reddy’s

Morrison Foerster advised Eton Pharmaceuticals (NASDAQ: ETON) in connection with its asset sale of several of its branded and generic injectable products to Dr. Reddy's Laboratories (NYSE: RDY).

The portfolio includes the Biorphen® (phenylephrine hydrocholoride) Injection and Rezipres® (ephedrine hydrochloride) Injection NDAs with nine separate combinations of strengths and presentations and one first-to-file approved ANDA for Cysteine Hydrochloride for the U.S. The acquisition will allow Eton to focus resources on its core rare disease business. It also complements Dr. Reddy's U.S. institutional business with limited competition injectable products and supports Dr. Reddy's efforts to accelerate and expand affordable medications for patients.

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The $50 million sale of its hospital products - Biorphen®, Rezipres®, and Cysteine Hydrochloride - will allow Eton to exclusively focus its resources on products that treat rare diseases going forward.

The MoFo deal team leading on the transaction was led by San Diego technology transactions partner Matthew Ferry, together with Boston associates Hannah Koo and Rohan George.

For more information, read Eton's press release.